The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI) has been selected to present significant findings at the upcoming ASCO Annual Meeting regarding their High-Value Cancer Care (HVCC) model. The study demonstrates remarkable improvements in patient care and cost efficiency:

Key outcomes include:

• 53% reduction in Emergency Department use
• 68% decrease in hospitalizations
• 75% lower odds of acute care facility death
• $12,000 cost savings per enrolled patient

According to TOI's Chief Medical Officer, Dr. Yale Podnos, these results validate their coordinated care approach in delivering superior clinical outcomes while significantly reducing costs for patients and payor partners.

Positive

• Significant 53% reduction in Emergency Department utilization
• Substantial 68% decrease in hospitalization rates
• 75% lower odds of acute care facility death, indicating improved patient outcomes
• Cost savings of $12,000 per enrolled patient

Negative

• None.

CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model.

“Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Department utilization and hospitalizations by over 50%, while simultaneously driving over $12,000 in cost savings per patient enrolled,” said Yale Podnos, MD, MPH, FACS, Chief Medical Officer at TOI. “This further validates the power of our care model in both improving clinical outcomes and providing value to our patients and payor partners through our highly coordinated, industry-leading approach to care.”

Summary of Outcomes of the Most Recent Clinical Trial Analysis:

• 53% Lower Emergency Department Use
• 68% Lower Hospitalizations
• 75% Lower Odds of Acute Care Facility Death
• Lower Total Cost of Care by $12,000 per Enrolled Patient

*Patel, et al. Improving care of older adults with cancer: A randomized trial. ASCO Annual Meeting Health Services Section, May 30, 2025.

About The Oncology Institute

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With over 120 employed clinicians and more than 700 teammates in over 70 clinic locations, TOI is changing oncology for the better.

For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

Solebury Strategic Communications
investors@theoncologyinstitute.com

FAQ

What are the key findings of TOI's High-Value Cancer Care model study presented at ASCO 2025?

The study showed 53% lower Emergency Department use, 68% lower hospitalizations, 75% lower odds of acute care facility death, and $12,000 cost savings per enrolled patient.

How much cost savings does The Oncology Institute's (TOI) HVCC model generate per patient?

The HVCC model generates cost savings of $12,000 per enrolled patient while maintaining quality clinical outcomes.

What is the impact of TOI's care model on hospitalization rates?

TOI's High-Value Cancer Care model reduces hospitalization rates by 68% compared to standard care.

How does The Oncology Institute's model affect emergency department utilization?

The model reduces Emergency Department utilization by 53% through their coordinated care approach.

What is the reduction in acute care facility death rates under TOI's care model?

The study shows 75% lower odds of acute care facility death for patients enrolled in TOI's High-Value Cancer Care model.